Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Genitourinary 3Endocrine 3CNS 3Thoracic 2Sarcoma 2NET 2Head & Neck 2Other solid neoplasm 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Solid Tumor 7Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Lymphoma, B-Cell 1Hematopoietic and Lymphoid System Neoplasm 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 5spartalizumab 2fludarabine 2budigalimab 2Nivolumab 2Cyclophosphamide 2venetoclax 1tislelizumab 1rovalpituzumab tesirine 1niraparib 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Ipilimumab 1Immunotherapy 1Fluorodeoxyglucose F18 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Fluorodeoxyglucose F18 × Other solid neoplasm × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡